Bristol Myers Squibb Foundation’s Diversity in Clinical Trials Career Development Program Grant Awarded to Dr. Oluwadamilola Oladeru

Drs. Oluwadamilola Oladeru and Julie BradleyUF Radiation Oncology Assistant Professor Oluwadamilola T. Oladeru (Lola), MD, MA, MBA has been awarded a $240,000, two-year grant from the Bristol Myers Squibb Foundation’s prestigious Diversity in Clinical Trials Career Development Program (BMSF DCTCDP).

The goal of the program is to build partnerships between clinical investigators and communities in order to increase the diversity of patients enrolled in clinical trials. Through sponsorship, support, training, and mentoring, the BMSF DCTCDP will develop 250 new Community-Oriented Clinical Trialists (COCT) equipped for investigator-initiated and industry-sponsored clinical trials, community outreach, and engagement processes and methods. Each Scholar will be mentored by an experienced Principal Investigator and will substantively participate in an active clinical trial.

During the program, Dr. Oladeru (above left) and Associate Professor Julie A. Bradley, MD (above right) will research the difference in cancer outcomes, acute and late toxicities between hypofractionated (3 weeks) proton therapy for women with invasive breast cancer that require regional nodal irradiation compared to standard fractionation (5 weeks) proton therapy. This will be a multiinstitutional study involving many proton centers across the country.

There is currently an ongoing study comparing proton therapy to standard photon therapy using the conventional treatment time of 5 weeks for women with locally advanced breast cancer; this study is taking the scientific question to the next level by investigating the role of shorter courses for these same patients using proton therapy which has better cardiac and lung sparing advantage.

“As our field have transitioned towards shorter lengths of radiation treatment for early-stage breast cancer patients, we believe this approach is also a safe and effective approach for patients with locally advanced disease requiring nodal irradiation, without comprising cancer and cosmetic outcomes while prioritizing quality of life and convenience of our patients.”.

For more information about the Bristol Myers Squibb Foundation for the prestigious Diversity in Clinical Trials Career Development Program, visit


U.S. News and World Report

Nationally ranked in 6 adult specialties and 6 pediatric specialties and rated high performing in 4 adult specialties and 5 procedures and conditions.